The ACR is launching new initiatives to reduce racial disparities in lupus clinical trials: Training to Increase Minority Enrollment in Lupus Clinical Trials with CommunitY Engagement (TIMELY) and new Continuing Medical Education (CME) for dermatologists and nephrologists.
African Americans have an increased risk of kidney failure, and new research shows that some of this risk is related to variations in a gene called apolipoprotein L1 (APOL1). Scientists will address racial disparities in kidney transplant outcomes.
Prominent gynecologic oncologist and surgeon B.J. Rimel, MD, recently was named medical director of the Cedars-Sinai Cancer Clinical Trials Office. She will serve as a medical liaison between clinical trial principal investigators and Cedars-Sinai Cancer leadership to ensure the quality of services provided to patients.
UC San Diego School of Medicine, Weill Cornell Medicine and Stanford Medicine have launched a three-year study to investigate new ways to treat or prevent major depression, accelerate effective treatments and develop predictive models to identify which treatments work best for individual patients.
Over 90 percent of patients with transfusion-dependent thalassemia, an inherited blood disorder, no longer needed monthly blood transfusions years after receiving gene therapy, according to an international Phase 3 clinical trial that for the first time included children younger than 12 years of age. Twenty-two patients were evaluated (ranging in age 4-34 years), including pediatric patients enrolled at Ann & Robert H. Lurie Children’s Hospital of Chicago.
Experts at Overlook are hoping that SurVaxM, a first-of-its-kind vaccine targeting a protein found in glioblastomas and other cancers, will give patients a better shot at long-term survival and improved function.
The Latest Research News in Cardiovascular Health
A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University has expanded its testing platform to evaluate ivermectin at a higher dose for a longer period of time.
Ivermectin is not approved by the FDA to treat or prevent COVID-19. Nonetheless, prescriptions of ivermectin by U.S. health care providers increased more than tenfold from 3,589 per week pre-COVID-19 to 39,102. In addition, the NIH, WHO and European Medicine Agency have all advised against using ivermectin to treat or prevent COVID-19. Researchers urge all health care providers to always prioritize compassion with reliable evidence on efficacy and safety. As such, they recommend a moratorium on prescribing ivermectin to treat or prevent COVID-19, except to provide the necessary evidence in data from large-scale randomized trials.
The UNM Comprehensive Cancer Center has opened the Targeted Agent and Profiling Utilization Registry (TAPURTM) Study, sponsored by the American Society of Clinical Oncology (ASCO). The clinical trial is cancer agnostic. It may help people who have rare cancer mutations and enable them to receive personalized cancer therapy.
Hackensack Meridian Children's Health is the Only Pediatric Health Network in New Jersey Undertaking Study into New Kidney Medication
Findings from a new study led by Yale Cancer Center researchers show enfortumab vedotin is effective in patients with muscle-invasive bladder cancer (MIBC) not eligible for cisplatin chemotherapy.
Mount Sinai researchers conducting clinical trials of a drug targeting a cancer gene found that it increased metastatic cancer patients’ survival and was able to work within the brain, according to a study published in Clinical Cancer Research in February.
A new report from the Cancer Research Institute on the global landscape of PD1/PDL1 immunotherapy clinical development
A trial investigating a potential electric biomarker for mild traumatic brain injury is now recruiting teenage and adult patients at The University of Texas Health Science Center at Houston (UTHealth Houston).
Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.
In a randomized clinical trial, overweight adults who increased their nightly sleep duration by about an hour reduced their daily caloric intake by an average of 270 kcal, which would lead to weight loss over time.
University Hospitals Cleveland Medical Center and UH Rainbow Babies and Children’s Hospital are participating in a Cochlear Americas’-sponsored clinical trial for an implantable hearing device in children 5 to 11 years of age who have been born with hearing loss that may be caused by craniofacial abnormalities. UH was the first site in the nation to kick off the trial.
Roswell Park Comprehensive Cancer Center is the first center to treat patients in a newly opened advanced-stage clinical trial utilizing the brain cancer vaccine SurVaxM, offering a new treatment option for patients who are dealing with a rare but deadly form of the disease. The multicenter randomized clinical trial is sponsored by MimiVax LLC, a company spun off from Roswell Park in 2012.
UChicago Medicine oncologist Wendy Stock, MD, has been named co-chair of the Leukemia Committee of the Alliance for Clinical Trials in Oncology.
Today, an analysis of these two patients published in Nature from the Penn researchers and colleagues from Children’s Hospital of Philadelphia explains the longest persistence of CAR T cell therapy recorded to date against CLL, and shows that the CAR T cells remained detectable at least a decade after infusion, with sustained remission in both patients.
The National Football League is funding a novel clinical trial by UC San Diego researchers to assess whether cannabis or CBD provide any post-game pain relief caused by athletic injury. Trial participants will be professional rugby players.
Sanjay Goel, MD, MS has been named director of Rutgers Cancer Institute of New Jersey's Phase I/Investigational Therapeutics Program, a multidisciplinary scientific group designed to develop new methods for the treatment of cancer in collaboration with colleagues across the RWJBarnabas Health system.
Kristi Taylor enrolled in a clinical trial at UTHealth Houston that is testing the efficacy and safety of fenebrutinib – a medication that inhibits the activity of certain malignant white blood cells – on the progression of disability in adult participants with primary progressive multiple sclerosis.
An ongoing study just published in The New England Journal of Medicine was pivotal in allowing mixed use of booster COVID-19 shots -- critical as the U.S. experienced the Omicron surge.
In adults who had previously received a full regimen of any of three COVID-19 vaccines granted Emergency Use Authorization (EUA) or approved by the Food and Drug Administration (FDA), an additional booster dose of any of these vaccines was safe and prompted an immune response, according to preliminary clinical trial results reported in The New England Journal of Medicine.
Ten years ago, on Jan. 23, 2012, the brand-new University of Kansas Clinical Research Center opened its doors.
The PFF embraces International Quality of Life Month as an opportunity to shine a spotlight on emerging treatments and supportive resources that can improve quality of life for patients affected by pulmonary fibrosis – a debilitating, often incurable lung disease affecting more than 250,000 Americans.
Researchers are studying whether a drug already approved to treat neurodegenerative diseases can be repurposed to help trauma surgeons determine whether nerves are severed or non-severed in peripheral nerve injuries.
• In an analysis of data from a recent clinical trial, researchers found that removing a race-based adjustment in the estimation of individuals’ kidney function had a small but potentially important impact on the inclusion of participants, with differing effects on Black and non-Black participants. • Removal of the race-based adjustment also influenced inclusion parameters such as participants’ severity of kidney function impairment at baseline as well as their risk of developing cardiovascular- and kidney-related outcomes.
A new study shows that an FDA-approved, pharmaceutical-grade formulation of CBD has an antiviral effect in human lung cells and mice, and shows a significant negative association with COVID infection in human patients.
University of Utah Health scientists are testing a new contraceptive gel for men. Based on preliminary research, the scientists believe the hormonal gel decreases a man’s sperm production––reducing his chances of fathering a child––without decreasing his sex drive.
In a phase 2 clinical trial conducted by Avalo Therapeutics and supported by researchers from Sanford Burnham Prebys, a significantly higher proportion of hospitalized patients with COVID-19 remained alive and free of respiratory failure for 28 days after receiving treatment with a new antibody called CERC-002. Unlike other experimental COVID therapies, CERC-002 does not target the virus itself, instead targeting the immune response associated with the virus to stop the disease from progressing before it becomes fatal.
In a new meta-analysis of randomized, placebo-controlled COVID-19 vaccine trials, researchers compared the rates of adverse events reported by participants who received the vaccines to the rates of adverse events reported by those who received a placebo injection.
Preliminary findings from Penn Medicine in an ongoing first-in-human clinical trial examining the safety, tolerability and feasibility of chimeric antigen receptor macrophage (CAR-M) has helped to establish the viability of this innovative immunotherapy, which advances the trailblazing scientific discovery of CAR T cell therapy—also pioneered at Penn—for solid cancer tumors and offers a promising new strategy in the fight against cancer. Preliminary data from the Phase 1 multi-center clinical trial, which uses a novel, gene-based cancer therapy with CAR-engineered macrophages to target recurrent or metastatic HER2-positive solid tumors, was presented during the recent Society for Immunotherapy of Cancer (SITC) annual meeting.
Oxytocin’s role in regulating and influencing social behavior is well known. Numerous ongoing clinical trials are focusing on the levels of the hormone in the brain but now a Florida State University research team has found evidence that oxytocin receptors outside of the brain may play an important role in shaping social behavior.
the NIH Collaboratory is donning a new name—NIH Pragmatic Trials Collaboratory—that will carry the highly successful program into the future with a continued commitment to transforming clinical research. The program was formerly known as the NIH Health Care Systems Research Collaboratory. Its new moniker reflects the program’s core mission of strengthening the national capacity to implement cost-effective, large-scale research studies conducted within healthcare delivery systems, also known as pragmatic trials.
 (1).png&width=400&height=400)
Prevention of eating disorders (EDs) is of high importance. However, digital programs with human moderation are unlikely to be disseminated widely. The aim of this study was to test whether a chatbot (i.e., computer program simulating human conversation) would significantly reduce ED risk factors (i.e., weight/shape concerns, thin-ideal internalization) in women at high risk for an ED, compared to waitlist control, as well as whether it would significantly reduce overall ED psychopathology, depression, and anxiety and prevent ED onset.
RareCyte Inc., ("RareCyte" or "The Company") a leading provider of Precision Biology products and services recognized over 100% sales growth in their Services business in 2021.
Wistar announces the initiation of a Phase 2 clinical study of VK-2019 in patients with advanced Epstein-Barr Virus (EBV)-positive nasopharyngeal carcinoma (NPC) and lymphoma.
Stuart Therapeutics, Inc. (STUART), a clinical stage, innovative ophthalmic therapeutic development company, today announced the topline results of the first in human Phase 2 clinical trial for its lead drug candidate, ST-100 in patients with dry eye disease.
Zahn, a professor of pediatrics and the director of the Guerin Family Congenital Heart Program in the Smidt Heart Institute, was the principal investigator for the multicenter clinical trial which led to the FDA's approval today. He says the new device will allow interventional cardiologists to treat more patients.
Generalized pustular psoriasis (GPP) is a rare, life-threatening skin condition for which there are no approved treatments. It is characterized by episodes of widespread eruptions of painful, sterile pustules (blisters of non-infectious pus). There is a high unmet need for treatments that can rapidly and completely resolve the signs and symptoms of GPP flares. Flares greatly affect a person’s quality of life and can lead to hospitalization with serious complications, including heart failure, renal failure, sepsis, and death.
Washington University School of Medicine in St. Louis is launching an international clinical trial aimed at preventing Alzheimer’s disease in people genetically destined to develop the illness at a young age. Unlike most other Alzheimer’s prevention trials, this one will enroll people before the disease has taken hold – up to 25 years before the expected onset of dementia.
An alternative statistical method honed and advanced by Cornell researchers can make clinical trials more reliable and trustworthy while also helping to remedy what has been called a “replicability crisis” in the scientific community.
Ian E. Krop, MD, PhD, has been appointed Chief Clinical Research Officer, Associate Cancer Center Director for Clinical Research, and Director of the Yale Cancer Center Clinical Trials Office.
The associate director for the clinical research program at UC Davis Comprehensive Cancer Center embarks on new leadership role in early 2022 as CEO of the International Association for the Study of Lung Cancer
.jpg&width=400&height=400)
Axicabtagene ciloleucel, known by the brand name Yescarta, is significantly more effective than the current standard of care in treating people with large B-cell lymphoma who relapse after the first line of treatment.
Results of a 12-month multicenter randomized clinical trial led by Erika Petersen, M.D., a professor of neurosurgery at the University of Arkansas for Medical Sciences (UAMS), were published online Nov. 29 in Diabetes Care, highlighting the benefits of a breakthrough treatment for patients with painful diabetic neuropathy (PDN).
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
